Journal of Vaccines & Vaccination

Adjuvant particle size vs. immunogenicity: Is there a correlation?

7^th Middle East - Global Summit and Expo on Vaccines & Vaccination

September 28-29, 2015 Dubai, UAE

Murali Bilikallahalli

MedImmune, USA

Scientific Tracks Abstracts: J Vaccines Vaccin

Abstract:

Oil-in-water emulsions have gained consideration as vaccine adjuvants in recent years due to their ability to elicit a differentiated immunogenic response compared to traditional aluminum salt adjuvants. Squalene, a cholesterol precursor, is a natural product with immunostimulatory properties, making it an ideal candidate for such oil-in-water emulsions. Particle size is a key parameter of these emulsions and its relationship to stability and adjuvanticity has not been extensively studied. This study evaluates the effect of particle size on the stability and immunogenicity of squalene emulsions. We investigated the effect of formulation parameters such as surfactant concentration on particle size, resulting in particles with average diameter of 80 nm, 100 nm, 150 nm, 200 nm, or 250 nm. Emulsions were exposed to shear and temperature stresses, and stability parameters such as pH, osmolarity, size, and in-depth visual appearance were monitored over time. In addition, adjuvanticity of different particle size was assessed in a mouse model using Respiratory Syncytial Virus Fusion protein (RSV-F) as a model antigen. Temperature dependent phase separation appeared to be the most common route of degradation occurring in the higher particle sizes emulsions. The emulsions below 150 nm size maintained stability at either 5°C or 25°C, and the 80 nm diameter ones showed no measurable changes in size even after one month at 40°C. In vivo studies using the emulsions as an adjuvant with RSV F antigen revealed that superior immunogenicity could be achieved with the 80 nm particle size emulsion.

Biography :

Murali got his PhD in Biophysical Chemistry from CFTRI (India), did postdoctoral studies at Kyoto (Japan) and Rice (USA) Universities, Assistant Professor at Texas Medical Branch (USA) and Principal Scientist at Pfizer Pharmaceuticals. He is a subject matter expert in the protein biophysics area over 20 years, and has been developing variety of biologic molecules as pharmaceutical drugs. Four approved products in the market (Xiapex, Flumist, Elelyso and Trumenba). He has won three young investigator awards (ASBMB-USA, ASPET-USA & JSPS- Japan), ten industry awards, and published over 45 original high impact research papers, expert reviews and book chapters. Currently, he serves on the Editorial boards of Drug Discovery Today, mAbs and Vaccines & Vaccinations.

Email: MuralidharaB@MedImmune.com